Skip to main content


Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Fig. 1

MET (a), p-MET (b), and HGF (c) overexpression thresholds in the cohort of HNSCC patients. ROC curves were used to calculate the optimal biomarker thresholds based on the progression endpoint for each protein. These scores, in correspondence, defined protein overabundance. Full lines represent the ROC curves; in dot lines, the diagonal reference lines

Back to article page